Home/Aptorum Group/Ronald Shigeta
RS

Ronald Shigeta

Independent Non-Executive Director

Aptorum Group

Aptorum Group Pipeline

DrugIndicationPhase
SACT-1Neuroblastoma and other solid tumorsPhase 1
ALS-4Staphylococcus aureus infections (including MRSA)Pre-clinical
CLS-1Obesity and Metabolic DisordersDiscovery
NAT-1Various CancersDiscovery
Aptorum Microbiome TherapeuticsClostridioides difficile Infection (CDI)Pre-clinical